Stora Enso Oyj R (0CXC)
London Exchange · UK · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 9.610 |
|---|---|
| 52-week range | 8.739 – 12.240 |
| Return, 1 month / 3 months | −9.4% / +8.5% |
| Return, 1 year / 3 years | +3.1% / −2.9% |
| Trend | Below its 200-day average |
| RSI (14) | 37 |
| Volatility (1 year) | 31.6% |
| Worst drawdown (1 year) | -24.3% |
| Average daily value traded | 6.54M EUR |
| Dividend yield | 2.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Stora Enso is a forest products company based in Finland. It makes renewable materials from wood, including packaging boards and cartons, pulp for further processing, paper for printing and writing, and sawn timber and wood products for construction. Its customers are converters, brand owners, publishers, printers and builders in Europe and other markets. The company also manages forests and offers wood-based solutions for packaging, building and biomaterials, drawing on its own plantations and mills.
The shares are listed on the London Exchange in UK under the code 0CXC, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Stora Enso Oyj R (0CXC) trades on the London Exchange in UK. It last closed at EUR 9.610 on 23 October 2026.
Its price-based Market X-Ray is 56 out of 100 (a fair price profile), ranking 1,652 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 3.1% and over the last three months it rose 8.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 46 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -3.4% | ||
| From 52-week high | -19.8% | ||
| Momentum | 59 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 8.5% | ||
| 6-month return | -5.7% | ||
| 12-month return, skipping the last month | 13.8% | ||
| Stability (higher is calmer) | 60 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 31.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -24.3% | ||
| Liquidity | 70 · Strong | Trades actively. | |
| Average daily value traded | 6.54M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 43 · Weak | Dividend is small or irregular. | |
| Dividend yield | 2.6% | ||
| Years with dividends | 5 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Income: Dividend is small or irregular.
Returns
| 1 week | −4.5% |
|---|---|
| 1 month | −9.4% |
| 3 months | +8.5% |
| 6 months | −5.7% |
| 1 year | +3.1% |
| 3 years | −2.9% |
| 5 years | −23.4% |
Signals
| 50-day / 200-day average | 10.010 / 9.945 |
|---|---|
| Golden / death cross (60 days) | Golden, 11 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.211 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 24 Sep 2026 | EUR 0.1200 |
| 25 Mar 2026 | EUR 0.1300 |
| 24 Sep 2025 | EUR 0.1200 |
| 21 Mar 2025 | EUR 0.1300 |
| 12 Dec 2024 | EUR 0.1000 |
| 21 Mar 2024 | EUR 0.1000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.